A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer

A Phase 1b, Open-Label, Dose-Escalation Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer

The purpose of this study is to determine whether BIIB022, Paclitaxel and Carboplatin are effective in the treatment of Treatment-Naive, Stage IIIB/IV Non-Small Cell Lung Cancer.

Inclusion Criteria:

• Age >/= 18 years old
• Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer
• ECOG Performance Status 0 or 1

Exclusion Criteria:

• History of another primary cancer within 3 years
• Any prior or concurrent investigational or standard therapy for treatment of NSCLC
• Prior anti-IGF-1R therapy
• Unstable diabetes